Видео ютуба по тегу Medicines: Dabrafenib

Dabrafenib Plus Trametinib for the Treatment of mNSCLC
Dabrafenib Plus Trametinib for the Treatment of mNSCLC
Dabrafenib and trametinib: a promising combination for the treatment of melanoma
Dabrafenib and trametinib: a promising combination for the treatment of melanoma
Dr. Daud on Dabrafenib/Trametinib Vs Immunotherapy in Melanoma
Dr. Daud on Dabrafenib/Trametinib Vs Immunotherapy in Melanoma
Long-Term Outcomes With Dabrafenib Plus Trametinib in BRAF V600-Mutant Melanoma
Long-Term Outcomes With Dabrafenib Plus Trametinib in BRAF V600-Mutant Melanoma
Treating BRAF V600E-mutant NSCLC with dabrafenib and trametinib
Treating BRAF V600E-mutant NSCLC with dabrafenib and trametinib
Dr. Robert on 5-Year Analysis of Dabrafenib/Trametinib in BRAF V600-Mutant Melanoma
Dr. Robert on 5-Year Analysis of Dabrafenib/Trametinib in BRAF V600-Mutant Melanoma
Dr. Sullivan Discusses Role of Dabrafenib Plus Trametinib in Melanoma
Dr. Sullivan Discusses Role of Dabrafenib Plus Trametinib in Melanoma
Dr. Weber on Side Effects of Dabrafenib/Trametinib in Melanoma
Dr. Weber on Side Effects of Dabrafenib/Trametinib in Melanoma
FDA Approval of Adjuvant Dabrafenib/Trametinib in BRAF+ Melanoma
FDA Approval of Adjuvant Dabrafenib/Trametinib in BRAF+ Melanoma
Dabrafenib - Tafinlar In a nutshell.
Dabrafenib - Tafinlar In a nutshell.
Continuous vs intermittent dosing of dabrafenib and trametinib in BRAF mutated melanoma
Continuous vs intermittent dosing of dabrafenib and trametinib in BRAF mutated melanoma
Dabrafenib and Trametinib in BRAF-Mutated NSCLC
Dabrafenib and Trametinib in BRAF-Mutated NSCLC
TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) Mechanism of Action for Advanced Melanoma
TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) Mechanism of Action for Advanced Melanoma
Phase III COMBI-d Study of Dabrafenib and Trametinib in Patients With Melanoma
Phase III COMBI-d Study of Dabrafenib and Trametinib in Patients With Melanoma
Practical Experience With Dabrafenib/Trametinib in NCSLC
Practical Experience With Dabrafenib/Trametinib in NCSLC